Surgery Partners, Inc. (NASDAQ:SGRY – Get Free Report) CFO David T. Doherty sold 6,733 shares of the firm’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $24.02, for a total value of $161,726.66. Following the sale, the chief financial officer now directly owns 150,868 shares in the company, valued at $3,623,849.36. The trade was a 4.27 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Surgery Partners Price Performance
Shares of NASDAQ SGRY opened at $23.60 on Friday. The stock has a market capitalization of $3.01 billion, a price-to-earnings ratio of -49.17, a PEG ratio of 19.21 and a beta of 2.73. The business has a 50-day moving average of $23.58 and a 200-day moving average of $26.04. The company has a debt-to-equity ratio of 0.99, a current ratio of 1.80 and a quick ratio of 1.66. Surgery Partners, Inc. has a fifty-two week low of $19.50 and a fifty-two week high of $33.97.
Surgery Partners (NASDAQ:SGRY – Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The company reported $0.39 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.01. The company had revenue of $864.40 million during the quarter, compared to analysts’ expectations of $828.09 million. Surgery Partners had a positive return on equity of 2.85% and a negative net margin of 2.03%. As a group, sell-side analysts predict that Surgery Partners, Inc. will post 0.67 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Surgery Partners
Wall Street Analyst Weigh In
Several analysts recently commented on the company. Royal Bank of Canada dropped their price objective on Surgery Partners from $49.00 to $35.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 20th. Macquarie lowered their target price on Surgery Partners from $34.00 to $33.00 and set an “outperform” rating for the company in a report on Tuesday, March 11th. Bank of America assumed coverage on Surgery Partners in a report on Monday, December 16th. They set a “buy” rating and a $30.00 target price for the company. Finally, JPMorgan Chase & Co. lowered their target price on Surgery Partners from $38.00 to $28.00 and set a “neutral” rating for the company in a report on Tuesday, December 3rd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $36.63.
Check Out Our Latest Stock Analysis on SGRY
Surgery Partners Company Profile
Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.
Further Reading
- Five stocks we like better than Surgery Partners
- How to Short Nasdaq: An Easy-to-Follow Guide
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- High Flyers: 3 Natural Gas Stocks for March 2022
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Surgery Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surgery Partners and related companies with MarketBeat.com's FREE daily email newsletter.